Cerrone increases Tiziana stake
Analysis based on 14 articles · First reported Jul 22, 2026 · Last updated Jul 22, 2026
The insider purchase signals confidence from the chairman, potentially boosting investor sentiment. However, the small size of the purchase relative to total shares may limit market impact.
On July 22, 2026, Tiziana Life Sciences announced that its Executive Chairman and Founder, Gabriele Cerrone, through Panetta Partners Limited, purchased 42,357 common shares at $0.99 per share, increasing his total holdings to 44,814,587 shares, representing 34.93% of issued share capital. Tiziana is a clinical-stage biopharmaceutical company developing intranasal foralumab, a fully human anti-CD3 monoclonal antibody, for neuroinflammatory and neurodegenerative diseases. The company has ongoing clinical trials for non-active secondary progressive multiple sclerosis.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard